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SUMMARY.-The antibody response to primary immunization with mono-
meric flagellin from Salmonella adelaide was studied in 61 patients with cancer
and antibody-producing capacity was correlated with survival. In 27 patients
suffering from " active " cancer, antibody-producing capacity was significantly
depressed (P < 0 05) as compared with sick but not cancerous controls; in
13 such patients who survived morethan6 months afterimmunization, antibody-
producing capacity was moderately depressed, whereas in 14 who survived less
than 6 months, the capacity was markedly depressed. In 34 patients with
" cured " cancer, by surgery and/or radiotherapy, antibody-producing capacity
was significantly greater than that of the " hospital " controls and patients with
" active " cancer, but yet was significantly less than that of healthy subjects.
Three explanations for the findings were considered: an immunodepressive
effect of general debility, an immunodepressive effect specific to cancer and, on
the other hand, the occurrence of cancer preferentially in individuals with an
impaired capacity for antibody production. The present findings gained added
relevance from recent evidence that a specific humoral immune response is
evoked by antigens of certain types at least of human cancer.
THE experimental induction of tumours in animals by chemical carcinogens or
viruses, e.g. polyoma virus and Moloney virus, is definitely facilitated by immuno-
depressive measures such as neonatal thymectomy or anti-lymphocyte serum
(Miller, Grant and Roe, 1963; Defendi and Roosa, 1965). However the part played
by the immunological system in the establishment and persistence ofhuman cancer
remains uncertain.
Renaud (1926) showed that patients with advanced cancer had impaired
cutaneous reactivity to tuberculin. Later, various workers claimed that cellular
immune responses were impaired in patients with advanced cancer; thus, as com-
pared with healthy subjects and patients with non-neoplastic diseases, there was
impaired delayed hypersensitivity to tuberculin, mumps and other microbial
antigens (Logan, 1956; Lamb, Pilney, Kelly and Good, 1962; Hughes and Mackay,
1965; Solowey and Rapaport, 1965), impaired induction of sensitivity to dinitro-
chlorobenzene and dinitrofluorobenzene (Southam, Brunschwig and Dixon, 1962),
and delayed rejection of allogeneic grafts of skin and tumour cells (Gardner and
Preston, 1962; Southam et al., 1962). Green, Anthony, Baldwin and Westrop
(1967) stated that this cellular immunodeficiency in advanced cancer was in some
way due to the cancer itself rather than to general debility.
Results of work on humoral immune responses in human cancer have been far
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less conclusive. Lytton, Hughes and Fulthorpe (1964), using the secondary
response to tetanus toxoid, showed that patients with cancer gave a lower response
than those with non-neoplastic diseases. However, workers with other antigens
including pneumococcal polysaccharides, diphtheria toxoid and tetanus toxoid
(Leskowitz, Phillipino, Hendrick and Graham, 1957), tularacmia and E. coli
antigens (Levin, Landy and Frei, 1964) and yellow fever vaccine (Southam, 1968)
could not demonstrate any such difforence.
A standard clinical test of antibody producing capacity, using immunization
with flagellin from Salmonella adelaide, has been developed in this Unit (Rowley
and Mackay, 1969). We applied this test to 61 patients with cancer. The experi-
mental design included patients with " active " cancer and patients with " cured "
cancer in whom the overt manifestations of cancer had been eradicated by surgery
or radiotherapy.
METHODS
Patient groups and controls
The " active " cancer group comprised 27 patients with non-lymphomatous
malignancies and the " cured " cancer group comprised 34 patients successfully
treated by surgery and/or radiotherapy; " cure " was judged by a follow-up period
of at least 3 years without any evidence ofrecurrence. None ofthese patients was
receiving chemotherapy or radiotherapy during the period of immunization.
The patients in the " active " cancer group ranged in age from 43 to 90 years,
mean 63 years. The primary sites oftheir cancer were pancreas (5 cases), stomach
(5 cases), oesophagus (2 cases), liver (3 cases), brain, lung, kidney, ovary, uterine
cervix, breast, testis, prostate, rectum and skin (1 case each), and unknown
(2 cases).
The patients in the " cured " cancer group ranged in age from 38 to 85 years,
mean 57 years. The primary sites of their cancer were uterine cervix (8 cases),
skin (7 cases), vulva (5 cases), colon (5 cases), stomach (2 cases), oral cavity (2 cases),
breast (2 cases) and uterine body, ovary and testis (1 case each).
The control groups were derived from patients in hospital-" hospital controls"
suffering from non-malignant diseases believed not to affect the function of the
immunological system, andhealthy subjects- " healthy controls ". The " active "
cancer group of patients was compared with a sex and age matched group of
" hospital controls "; the mean age for this was 62 years. The " cured " cancer
group was compared with a sex and age matched group of " hospital controls " and
also with a similarly matched group of " healthy controls "; the mean age ofthese
2 control groups was the same, namely 55 years.
Immunization and titration
Monomeric flagellin from Salmonella adelaide was prepared as described by Ada,
Nossal, Pye and Abbot (1964), passed through a sterile Seitz filter (No. 9 pad) and
stored at - 20° C. until use. Spontaneous polymerization of monomeric flagellin
occurs, so that the antigen was depolymerized immediately before injection by
treatment with a 1/20 volume of N hydrochloric acid, allowed to stand for 20
minutes, neutralized with an equal volume of N sodium hydroxide, and diluted to
50 ,ag. per ml. in phosphate buffered saline, pH 7 0. Five micrograms offlagellin in
0.1 ml. ofbuffer was injected subcutaneously into the forearm. Samples of serum
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were obtained before injection, and thereafter at 6-8 days (" one week "), 13-21
days (" two weeks "), 34-49 days (" six weeks ") and 62-77 days (" ten weeks ").
Total antibody and antibody remaining after treatment of serum with 2-
mercapto-ethanol (ME) for 1 hour at 370 C. (ME-resistant antibody) were titrated
by tanned cell haemagglutination using sheep red blood cells coated with poly-
merized flagellin (Wistar, 1968; Rowley and Mackay, 1969). Geometric mean
titres ofantibody were calculated for patients in the various groups, titres below 5
being given the value 1. Mean differences between the groups were compared by
the Rank test. ME-resistant antibody to flagellin has been shown to correspond
with IgG antibody by gel filtration ofserum through a column ofSephadex G-200.
ME-sensitive antibody to flagellin was present entirely in the IgM peak and
ME-resistant antibody entirely in the IgG peak (Rowley, 1970, unpublished
data).
Studies on cellular immunity
Studies on cellular immunity were not included in the original design of our
experiments, mainly because monomeric flagellin does not induce a clear delayed
hyper-sensitivity response in man. However during the course of this work, the
technique was developed in this Institute for counting " antigen-binding cells " in
human peripheral blood, using radioiodine-labelled flagellin as antigen (Dwyer and
Mackay, 1970). In brief, blood samples obtained before and 2 weeks after
immunization with flagellin were defibrinated and layered on to a mixture of
methyl cellulose andurographinfor30minutes. Supernatant containing 10million
leucocytes was removed and centrifuged, the cell pellet was resuspended in 0-2 ml.
ofDulbecco's medium containing 10% fetal calf serum, flagellin labelled with 125J
was added and the mixture was kept at 00 C. for 30 minutes. The mixture ofcells
andantigenwasresuspendedandlayered onto 3 ml. ofagradientoffetal calfserum
andphosphate buffered saline, then centrifuged. This was repeated three times to
remove antigen not bound to cells. The washed cells were smeared on to gelatin
coated slides and fixed for 30 minutes in methanol 89%, acetic acid 1% and
distilled water 10%. Forautoradiography the slides were dippedin KodakN.T.B.
2 photographic emulsion and exposed for 7 days, developed, and stained with
Giemsa. One thousand lymphocytes in five different areas of the slide were
counted and the number of cells labelled with 50 or more grains were scored as
antigen-binding lymphocytes.
At the time of immunization with flagellin the lymphocyte count in the
peripheral blood was determined in the routine haematology laboratory. The
mean count for patients in the " active " cancer group was compared with that for
the corresponding " hospital control " group.
RESULTS
The results are shown in Table I and in Fig. 1-5.
Natural antibody toflagellin
Natural antibody to flagellin can be detected in most individuals before
immunization with flagellin (Rowley and Mackay, 1969). It is IgM in class and
appears shortly afterbirth (Rowley, 1970). Itwaspresentin 84% ofthe " active "
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FIG. 1.-Geometric mean titres oftotal antibody 0 0, and IgG antibody 0-0----- O to
flagellin in 27 patients with " active " cancer were significantly lower (P < 0 05) than in
54 matched hospital controls (A A and A-------A). Vertical bars in all figures
represent one standard error of the mean.
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FIG. 2.-Geometric mean titres oftotal antibody 0 0, and IgG antibody 0-0----- O to
flagellin in 13 patients with " active " cancer surviving more than 6 months after immuniza-
tion; only the titre for IgG was significantly lower than that ofhospital controls.
cancer group, in 93% of the " cured " cancer group and in 96% of the controls;
there were no significant differences in the mean titres between the 3 groups (see
Table I).
Humoral immune response toflagellin
" Active " cancer (27 patients).-The mean peak titre of total antibody to
flagellin 2 weeks after injection was 342, and was significantly less (P < 0.05) than
the mean of 1002 for the hospital controls. The mean peak titre ofIgG antibody
was even more markedly depressed than in the hospital controls, the respective
means being 11 versus 61 (P < 0.01). The mean titres of both total and IgG
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FIG. 3.-Geometric mean titres oftotal antibody 0 0, and IgG antibody 0-0----- O to
flagellin in 14 patients with " active " cancer surviving less than 6 months after immuniza-
tion were significantly lower (P < 0 05) thap those ofhospital controls.
WEEKS AFTER INJECTION
FIG. 4.-Geometric mean titres oftotal antibody 0 0, and IgG antibody 0- -0 to
flagellin in 34patientswith " cured " cancer. Meantitres oftotalantibodyfellbetweenthose
for the healthy controls (A) and hospital controls (B), whilst titres of IgG antibody did not
differ significantly for the three groups.
antibody 10 weeks after immunization were also significantly lower in the patients
than in the controls, the differences being comparable to those at 2 weeks (Fig. 1).
The results for the 27 patients in the " active " cancer group were further
analysed according to the duration of survival after the test of the immune
response (Fig. 2 and 3). For 13 patients who survived more than 6 months the
mean peak titre for total antibody was slightly lower than that for the hospital
controls (420 versus 857), but the IgG titre was significantly lower (8 versus 66,
P < 0.01). For 14 patients who survived less than 6 months the antibody
response was markedly depressed; the mean peak titres for total and IgG antibody
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FIG. 5.-Geometric mean titres oftotal antibody 0 0, and IgG antibody 0-------0 to
flagellin in patients with " cured " cancer were significantly higher (P < 0 01) than in
patients with " active " cancer.
were significantly lower (P < 0-05) thaninthe hospital controls (276 and 15 versus
1190 and 57) and the antibody titres were poorly maintained (Fig. 3).
" Cured " cancer (34 patients).-The peak titres oftotal and IgG antibody to
flagellin were significantly higher thanthoseforthe correspondinghospital controls
(Fig. 4), in contrast with the " active " cancer group. However, the mean peak
titresweresignificantlylower (P < 0.05) thanthoseofthehealthycontrols. It was
noteworthythatwhenthis " cured " cancergroupwascompared with the " active "
cancergroup, theirantibody-producing capacitywassignificantlygreater (P = 0.01)
in regard to both total and IgG antibody (Fig. 5).
Studies on cellular immunity
Antigen-binding cells in blood after immunization.-The immune response to
flagellin of4 patients in the subgroup of " active " cancer with less than 6 months
survival was further studied by serial counts in blood of lymphocytes capable of
binding this antigen-antigen-binding lymphocytes. In normal subjects not
immunized with flagellin the number of antigen-binding lymphocytes in blood is
3-5 per 1000 lymphocytes and after immunization there is a rise, beginning on
day 4 and peaking at days 7-10, to 40-50 per 1000 lymphocytes, thus preceding by
a few days the peak titre ofantibody (Dwyer andMackay, 1970). The response of
4 patients with cancer compared with that ofhospital patients with non-neoplastic
diseases is shown in Table II; in all 4 patients there was a considerably lower peak
count of antigen-binding lymphocytes after immunization.
DISCUSSION
A well standardized test for measuring antibody-producing capacity in man has
been developed in this Unit; this is the response to the subcutaneous injection of
5 ag. ofthe purified bacterial protein flagellin over a 10 week period (Rowley and
Mackay, 1969). Using this test in patients with miscellaneous non-lymphoid
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TABLE II.-Antigen-Binding Lymphocytes in Blood 10-14 Days after
Immunization withFlagellin
Counts of antigen-binding lymphocytes/1000
10-14 days after
Subjects Before immunization immunization
4 patients with cancer* 4, 2, 4, 6 20, 26, 13, 26
Mean 4+ S.D. 1 Mean 21 S.D. 6
13 controls (with non-neoplastic diseases) Mean 5 S.D. 2 Mean 45+ S.D. 20
Patients versus controls No significance P < 0.05
* Carcinoma of bile duct, ovary, lung, stomach.
cancers, we demonstrated a significant impairment of the primary immune
response affecting the production ofboth IgM and IgG antibody, particularly IgG.
This has not, to our knowledge, been shown previously, although Barr and Fairley
(1961) and Libansky (1965) obtained equivalent data in patients with lymphoid
malignancies, i.e. Hodgkin's disease and lymphomas, and Lytton et al. (1964)
showed impaired secondary rather than primary immune response in patients with
non-lymphoid cancers. Moreover, using the response to tetanus toxoid, Lytton
et al. (1964) found as we did that a poor antibody response correlated with a short
survival.
We can offer three explanations for our findings of a marked depression in
antibody-producing capacityinpatients with " active " cancer and anearlynormal
response in those with " cured " cancer.
The first explanation is a depressive influence of general debility on antibody
production. We attempted to control for this by comparing the patients suffering
from cancer with patients in hospital with non-neoplastic diseases-" hospital
controls ". It has been shown (Rowley and Mackay, 1969) that patients with
miscellaneous illnesses respond to flagellin less well than healthy subjects. How-
ever, since there are no objective measures of" debility ", we cannot state whether
ourpatientswith " active " cancer andourhospital controlsweretrulycomparable.
The second explanation is an immunodepressive effect specific to cancer. For
example there could be a general cytotoxic effect of a tumour product affecting
particularly lymphocytes, or " exhaustion " of the immune system from either
prolonged blockade with tumour products or a prolonged immune reaction to the
cancer. As evidence forthis fromthepresent studypatients with " active " cancer
had lymphopenia and an impaired response of antigen-binding lymphocytes in
blood after immunization with flagellin. We have already cited earlier in this
paper other evidence for impaired lymphocyte function in cancer, viz. depressed
delayed cutaneous hypersensitivity to tuberculin and other microbial antigens and
delayed rejection of allogeneic grafts of skin and cancer cells.
The third explanation ofour findings is that immunodepression in patients with
cancer is a cause rather than an effect; cancer is either more prone to occur or
become established in subjects with relatively weak immune responses. This
would be in keeping with the concept of immunological surveillance as a defence
against neoplasia (Burnet, 1968). The near normal response of our " cured "
cancer patients is consistent with this in that control oftumour growth by surgery
and/or radiotherapy would tend to occur in patients with well-developed immune
responses. The finding in this group of patients that their antibody-producing
capacity, whilst greater than the sickhospital controls, was significantly lower than
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the healthy controls might be cited as a factor contributing to the initial emergence
of their cancer. Admittedly the part played by the humoral antibody system in
" immunological surveillance " over neoplasia is uncertain and may well be com-
plex, as is the case in transplantation immunity. On one side, humoral antibody
can " enhance " the growth and spread of cancer by coating the antigenic sites so
preventing elimination by the cellular immune system (Pollock and Tripodi, 1967).
On the other side, there are reports (Fisherman, 1960; Mackay, 1966) which state
that the incidence ofallergic diseases in patients with malignancy was significantly
lower as compared with non-cancerous controls. The point to be made is that the
two efferent expressions of immunity, cellular and humoral, cannot be dissociated
even though in given situations one or the other may appear to have a predominant
influence.
We would conclude by citing evidence that a humoral immune response is
invoked by antigens of human cancers, e.g. melanoma (Lewis et al., 1969) and
colonic cancer (Thomson, Krupey, Freedman and Gold, 1970). Ifthis is a general
phenomenon and is part of a host defence against cancer, then our findings of
impaired antibody-producing capacity in cancer seem to have considerable
relevance.
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